Scarica l'app Stockscreener
17.29
0.23%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$17.33
Aprire:
$17.34
Volume 24 ore:
9.52M
Relative Volume:
0.88
Capitalizzazione di mercato:
$20.14B
Reddito:
$14.57B
Utile/perdita netta:
$-296.50M
Rapporto P/E:
-66.76
EPS:
-0.259
Flusso di cassa netto:
$1.64B
1 W Prestazione:
+6.27%
1M Prestazione:
+9.92%
6M Prestazione:
+34.45%
1 anno Prestazione:
+86.52%
Intervallo 1D:
$17.23
$17.67
Intervallo di 1 settimana:
$16.12
$17.67
Portata 52W:
$8.625
$17.67
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.29 | 20.18B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
PFE5003242 Bond Profile — Key Metrics - TradingView
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Khaitan & Co Advised Viatris Inc. On Secondary Sale Of Shares Held in Biocon - BW Legal World
Viatris stock hits 52-week high at $17.54 - Investing.com UK
PFE5282058 Bond Profile — Key Metrics - TradingView
Viatris Inc (VTRS) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Looks to New Launches and Cost Savings for Long-Term Growth - Morningstar
XS332542958 Bond Profile — Key Metrics - TradingView
ETFs Investing in Viatris, Inc. Stocks - TradingView
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows - WTVB
Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon - Business Standard
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows - Reuters
(VTRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viatris shares break six-session winning streak - MSN
BofA Securities Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS) - simplywall.st
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - AOL.com
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? - Yahoo Finance
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results - Yahoo Finance
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now - Insider Monkey
Viatris Inc. Class Action: The Gross Law Firm Reminds Viatris In - GuruFocus
VTRS Stock Price and Chart — NASDAQ:VTRS - TradingView
A Look at Viatris Inc (VTRS) After 3.1% Gain -- GF Value $11.02 vs Price $16.70 - GuruFocus
Viatris (VTRS) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Viatris Refinances $247.7 Million Term Loan - Moomoo
VTRSViatris Inc Dividends - Finviz
Form 4 Viatris Inc For: 1 July By Investing.com - Investing.com Canada
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees - Stock Titan
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees - Stock Titan
Viatris to Report Second-Quarter 2026 Financial Results on Augus - GuruFocus
ViatrisEnters Amended And Restated Term Loan Credit Agreement On July 1, 2026SEC Filing - TradingView
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility - TradingView
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal - Stock Titan
Viatris Inc Enters Into Amended and Restated Term Loan Credit Agreement for JPY 40,000,000,000 Senior Unsecured Term Loan Facility - marketscreener.com
Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025Contact Levi & Korsinsky - The National Law Review
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205 - simplywall.st
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Securities Fraud Class Action Filed Against Viatris Inc. (VTRS) Levi & Korsinsky Reminds Investors of June 3, 2025 - The National Law Review
Viatris reports positive phase 3 results for IgAN drug in Japan By Investing.com - Investing.com India
(VTRS) Risk Channels and Responsive Allocation - Stock Traders Daily
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN - MSN
Viatris reports positive phase 3 results for IgAN drug in Japan - Investing.com South Africa
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.25%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):